MAIA Biotechnology (MAIA) CEO & 10% owner Vlad Vitoc increases stake with 72,000-share purchase

Rhea-AI Filing Summary

MAIA Biotechnology (MAIA) insider Vlad Vitoc, the company’s Chief Executive Officer, director and a 10% owner, reported open-market purchases of MAIA common stock. On November 28, 2025, he bought 50,000 shares at a weighted average price of $1.1366 per share. On November 26, 2025, he bought an additional 22,000 shares at a weighted average price of $1.0463 per share.

After these transactions, Vitoc directly beneficially owns 881,421 shares of MAIA common stock and indirectly beneficially owns 210,000 shares through his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.

Insider Trade Summary

Net Buyer: 72,000 shares ($79,849)

Net Buy 3 txns

Insider Vitoc Vlad

Role Chief Executive Officer

Bought 72,000 shs ($80K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	50,000	$1.1366	$57K
Purchase	Common Stock	22,000	$1.0463	$23K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 881,421 shares (Direct); Common Stock — 210,000 shares (Indirect, See Footnote)

Footnotes (1)

1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.1283 to $1.1416, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.0145 to $1.0587, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. These securities are beneficially owned by Mr. Vitoc's spouse. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vitoc Vlad

(Last) (First) (Middle)

444 WEST LAKE STREET,

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/28/2025		P		50,000	A	$1.1366(1)	881,421	D
Common Stock	11/26/2025		P		22,000	A	$1.0463(2)	853,421	D
Common Stock								210,000	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.1283 to $1.1416, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

2. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.0145 to $1.0587, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

3. These securities are beneficially owned by Mr. Vitoc's spouse. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

	/s/ Vlad Vitoc	11/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MAIA (MAIA) report in this Form 4?

The filing reports that Vlad Vitoc, MAIA Biotechnology’s Chief Executive Officer, director and 10% owner, purchased additional shares of the company’s common stock in open-market transactions.

How many MAIA shares did Vlad Vitoc purchase and at what prices?

Vlad Vitoc purchased 50,000 shares of MAIA common stock at a weighted average price of $1.1366 per share on November 28, 2025, and 22,000 shares at a weighted average price of $1.0463 per share on November 26, 2025.

How many MAIA shares does Vlad Vitoc beneficially own after these transactions?

Following the reported purchases, Vlad Vitoc beneficially owns 881,421 shares of MAIA common stock directly and 210,000 shares indirectly through his spouse.

What does the weighted average price mean in the MAIA insider purchase disclosure?

The filing states that the reported prices of $1.1366 and $1.0463 are weighted average prices, reflecting multiple trades executed in price ranges of $1.1283–$1.1416 and $1.0145–$1.0587 respectively. Full trade details are available upon request from the reporting person.

How is the 210,000-share indirect MAIA ownership held for Vlad Vitoc?

The filing explains that 210,000 shares of MAIA common stock are beneficially owned by Mr. Vitoc’s spouse, and he disclaims beneficial ownership of these shares except to the extent of his pecuniary interest in them.

What is Vlad Vitoc’s role at MAIA Biotechnology?

According to the filing, Vlad Vitoc is a director, a 10% owner, and serves as the company’s Chief Executive Officer.